Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
van der Heijde D, Gensler L, Maksymowych W, Landewe R, Rudwaleit M, Bauer L, Hoepken B, Kumke T, Kim M, Deodhar A (2021)
In: Abstract Supplement ACR Convergence 2021. American College of Rheumatology (Ed); Arthritis & Rheumatology, 73(S9). Hoboken: Wiley: 1896-1899.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
van der Heijde, Desiree;
Gensler, Lianne;
Maksymowych, Walter;
Landewe, Robert;
Rudwaleit, MartinUniBi;
Bauer, Lars;
Hoepken, Bengt;
Kumke, Thomas;
Kim, Mindy;
Deodhar, Atul
herausgebende Körperschaft
American College of Rheumatology
Einrichtung
Erscheinungsjahr
2021
Titel des Konferenzbandes
Abstract Supplement ACR Convergence 2021
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
73
Ausgabe
S9
Seite(n)
1896-1899
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2961897
Zitieren
van der Heijde D, Gensler L, Maksymowych W, et al. Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study. In: American College of Rheumatology, ed. Abstract Supplement ACR Convergence 2021. Arthritis & Rheumatology. Vol 73. Hoboken: Wiley; 2021: 1896-1899.
van der Heijde, D., Gensler, L., Maksymowych, W., Landewe, R., Rudwaleit, M., Bauer, L., Hoepken, B., et al. (2021). Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study. In American College of Rheumatology (Ed.), Arthritis & Rheumatology: Vol. 73. Abstract Supplement ACR Convergence 2021 (pp. 1896-1899). Hoboken: Wiley. https://doi.org/10.1002/art.41966
van der Heijde, Desiree, Gensler, Lianne, Maksymowych, Walter, Landewe, Robert, Rudwaleit, Martin, Bauer, Lars, Hoepken, Bengt, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. 2021. “Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study”. In Abstract Supplement ACR Convergence 2021, ed. American College of Rheumatology, 73:1896-1899. Arthritis & Rheumatology. Hoboken: Wiley.
van der Heijde, D., Gensler, L., Maksymowych, W., Landewe, R., Rudwaleit, M., Bauer, L., Hoepken, B., Kumke, T., Kim, M., and Deodhar, A. (2021). “Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study” in Abstract Supplement ACR Convergence 2021, American College of Rheumatology ed. Arthritis & Rheumatology, vol. 73, (Hoboken: Wiley), 1896-1899.
van der Heijde, D., et al., 2021. Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study. In American College of Rheumatology, ed. Abstract Supplement ACR Convergence 2021. Arthritis & Rheumatology. no.73 Hoboken: Wiley, pp. 1896-1899.
D. van der Heijde, et al., “Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study”, Abstract Supplement ACR Convergence 2021, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 73, Hoboken: Wiley, 2021, pp.1896-1899.
van der Heijde, D., Gensler, L., Maksymowych, W., Landewe, R., Rudwaleit, M., Bauer, L., Hoepken, B., Kumke, T., Kim, M., Deodhar, A.: Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study. In: American College of Rheumatology (ed.) Abstract Supplement ACR Convergence 2021. Arthritis & Rheumatology. 73, p. 1896-1899. Wiley, Hoboken (2021).
van der Heijde, Desiree, Gensler, Lianne, Maksymowych, Walter, Landewe, Robert, Rudwaleit, Martin, Bauer, Lars, Hoepken, Bengt, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. “Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non-Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study”. Abstract Supplement ACR Convergence 2021. Ed. American College of Rheumatology. Hoboken: Wiley, 2021.Vol. 73. Arthritis & Rheumatology. 1896-1899.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar